Philana Ling Lin Selected Research

Cytokines

3/2024	Antibiotic treatment modestly reduces protection against Mycobacterium tuberculosis reinfection in macaques.
12/2023	Antibiotic treatment does not abrogate protection against Mycobacterium tuberculosis reinfection in Macaques.
1/2023	Characterization of natural killer cells in the blood and airways of cynomolgus macaques during Mycobacterium tuberculosis infection.
1/2019	CD4CD8 Double Positive T cell responses during Mycobacterium tuberculosis infection in cynomolgus macaques.
1/2018	Low Levels of T Cell Exhaustion in Tuberculous Lung Granulomas.
4/2016	Computational and Empirical Studies Predict Mycobacterium tuberculosis-Specific T Cells as a Biomarker for Infection Outcome.
1/2016	Effects of B Cell Depletion on Early Mycobacterium tuberculosis Infection in Cynomolgus Macaques.
1/2015	Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization.
3/2011	Simian immunodeficiency virus-induced changes in T cell cytokine responses in cynomolgus macaques with latent Mycobacterium tuberculosis infection are associated with timing of reactivation.
5/2007	Tumor necrosis factor and tuberculosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Philana Ling Lin Research Topics

Disease

30	Tuberculosis (Tuberculoses) 12/2023 - 06/2004
26	Infections 03/2024 - 08/2005
21	Granuloma 12/2023 - 06/2004
4	Inflammation (Inflammations) 03/2024 - 01/2016
4	Reinfection 03/2024 - 10/2018
4	Pneumococcal Infections 08/2018 - 04/2003
4	Latent Infection 08/2012 - 10/2007
3	Pneumonia (Pneumonitis) 01/2017 - 08/2014
2	Coinfection 03/2024 - 12/2023
2	Pulmonary Tuberculosis 11/2023 - 01/2020
2	Latent Tuberculosis 05/2011 - 08/2005
1	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 01/2020
1	Virus Diseases (Viral Diseases) 01/2020
1	Lung Injury 01/2020
1	Pneumococcal Pneumonia 06/2017
1	Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis) 09/2015
1	Extensively Drug-Resistant Tuberculosis 12/2014
1	Chronic Granulomatous Disease 03/2009
1	Impetigo (Impetigo Contagiosa) 03/2009
1	Persistent Infection 05/2007

Drug/Important Bio-Agent (IBA)

11	CytokinesIBA 03/2024 - 08/2005
9	VaccinesIBA 11/2023 - 01/2012
7	Anti-Bacterial Agents (Antibiotics)IBA 03/2024 - 12/2014
7	Conjugate VaccinesIBA 08/2018 - 04/2003
5	AntigensIBA 12/2023 - 01/2012
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2016 - 08/2005
4	RNA (Ribonucleic Acid)IBA 12/2023 - 01/2018
4	Proteins (Proteins, Gene)FDA Link 12/2023 - 07/2013
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021 - 12/2016
3	Interleukin-17 (Interleukin 17)IBA 01/2016 - 01/2015
2	LigandsIBA 12/2023 - 06/2004
2	Transcription Factors (Transcription Factor)IBA 01/2023 - 01/2022
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 09/2013
2	Linezolid (Zyvox)FDA Link 01/2020 - 12/2014
2	Biomarkers (Surrogate Marker)IBA 10/2018 - 04/2016
2	Interleukin-10 (Interleukin 10)IBA 01/2016 - 01/2016
2	Interleukin-2 (IL2)IBA 01/2016 - 01/2016
2	Interferon-gamma (Interferon, gamma)IBA 10/2009 - 07/2006
2	ChemokinesIBA 08/2005 - 06/2004
1	Immunoglobulin IsotypesIBA 12/2023
1	Immunoglobulin M (IgM)IBA 12/2023
1	Immunoglobulin G (IgG)IBA 12/2023
1	Immunoglobulin A (IgA)IBA 12/2023
1	arabinomannanIBA 12/2023
1	Polysaccharides (Glycans)IBA 12/2023
1	AntibodiesIBA 12/2023
1	ProteomeIBA 12/2023
1	Interleukin-15 (Interleukin 15)IBA 12/2023
1	Immunodominant EpitopesIBA 01/2023
1	Moxifloxacin (Avelox)FDA Link 01/2023
1	Formyl Peptide Receptors (Formyl Peptide Receptor)IBA 01/2021
1	BCG Vaccine FDA Link 01/2020
1	InterferonsIBA 01/2020
1	Interleukin-1 (Interleukin 1)IBA 01/2020
1	Rifampin (Rifampicin)FDA LinkGeneric 01/2020
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2020
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2020
1	Granzymes (Granzyme)IBA 01/2020
1	AerosolsIBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 10/2018
1	Interleukin-6 (Interleukin 6)IBA 01/2016
1	Neutralizing AntibodiesIBA 01/2016
1	Rituximab (Mabthera)FDA Link 01/2016
1	Indicators and Reagents (Reagents)IBA 03/2015
1	Oxazolidinones (2 Oxazolidone)IBA 12/2014
1	Therapeutic UsesIBA 12/2014
1	Drug CombinationsIBA 09/2013
1	Nitric Oxide Synthase (NO Synthase)IBA 07/2013
1	ArginaseIBA 07/2013
1	Protein Isoforms (Isoforms)IBA 07/2013
1	EnzymesIBA 07/2013
1	Oxygen (Dioxygen)IBA 08/2012
1	Metronidazole (Metric)FDA LinkGeneric 08/2012
1	Isoniazid (Ftivazide)FDA LinkGeneric 05/2011
1	Interleukin-4 (Interleukin 4)IBA 03/2011
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 02/2010
1	Adalimumab (Humira)FDA Link 02/2010
1	CC ChemokinesIBA 06/2004

Therapy/Procedure

7	Therapeutics 02/2024 - 10/2007
2	Transplantation 05/2017 - 02/2017
1	Art Therapy 10/2020
1	Intravenous Administration 01/2020
1	Drug Therapy (Chemotherapy) 09/2013
1	Duration of Therapy 08/2012
1	Aftercare (After-Treatment) 01/2012
1	Cholecystectomy 03/2009